vs

Side-by-side financial comparison of BGC Group, Inc. (BGC) and BIOMARIN PHARMACEUTICAL INC (BMRN). Click either name above to swap in a different company.

BGC Group, Inc. is the larger business by last-quarter revenue ($955.5M vs $766.2M, roughly 1.2× BIOMARIN PHARMACEUTICAL INC). BIOMARIN PHARMACEUTICAL INC runs the higher net margin — 13.8% vs 8.4%, a 5.4% gap on every dollar of revenue. On growth, BGC Group, Inc. posted the faster year-over-year revenue change (43.8% vs 3.0%). Over the past eight quarters, BGC Group, Inc.'s revenue compounded faster (48.2% CAGR vs 3.7%).

BGC Group, Inc. is an American global financial services company based in New York City and London. Originally formed as part of the larger Cantor Fitzgerald organization, BGC Partners became its own entity in 2004.

BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies (ERTs). BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria (PKU).

BGC vs BMRN — Head-to-Head

Bigger by revenue
BGC
BGC
1.2× larger
BGC
$955.5M
$766.2M
BMRN
Growing faster (revenue YoY)
BGC
BGC
+40.8% gap
BGC
43.8%
3.0%
BMRN
Higher net margin
BMRN
BMRN
5.4% more per $
BMRN
13.8%
8.4%
BGC
Faster 2-yr revenue CAGR
BGC
BGC
Annualised
BGC
48.2%
3.7%
BMRN

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
BGC
BGC
BMRN
BMRN
Revenue
$955.5M
$766.2M
Net Profit
$80.6M
$106.0M
Gross Margin
74.6%
Operating Margin
16.9%
Net Margin
8.4%
13.8%
Revenue YoY
43.8%
3.0%
Net Profit YoY
EPS (diluted)
$0.17
$0.54

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BGC
BGC
BMRN
BMRN
Q1 26
$955.5M
$766.2M
Q4 25
$638.6M
$874.6M
Q3 25
$620.8M
$776.1M
Q2 25
$648.0M
$825.4M
Q1 25
$534.6M
$745.1M
Q4 24
$475.2M
$747.3M
Q3 24
$448.9M
$745.7M
Q2 24
$435.0M
$712.0M
Net Profit
BGC
BGC
BMRN
BMRN
Q1 26
$80.6M
$106.0M
Q4 25
$14.4M
$-46.6M
Q3 25
$27.9M
$-30.7M
Q2 25
$57.5M
$240.5M
Q1 25
$55.2M
$185.7M
Q4 24
$25.2M
$124.9M
Q3 24
$14.7M
$106.1M
Q2 24
$37.8M
$107.2M
Gross Margin
BGC
BGC
BMRN
BMRN
Q1 26
74.6%
Q4 25
68.5%
Q3 25
82.0%
Q2 25
81.8%
Q1 25
79.7%
Q4 24
81.8%
Q3 24
74.7%
Q2 24
81.7%
Operating Margin
BGC
BGC
BMRN
BMRN
Q1 26
16.9%
Q4 25
3.9%
-5.1%
Q3 25
5.4%
-6.0%
Q2 25
11.6%
33.5%
Q1 25
15.0%
30.0%
Q4 24
5.7%
21.6%
Q3 24
4.4%
15.3%
Q2 24
12.7%
16.9%
Net Margin
BGC
BGC
BMRN
BMRN
Q1 26
8.4%
13.8%
Q4 25
2.3%
-5.3%
Q3 25
4.5%
-4.0%
Q2 25
8.9%
29.1%
Q1 25
10.3%
24.9%
Q4 24
5.3%
16.7%
Q3 24
3.3%
14.2%
Q2 24
8.7%
15.1%
EPS (diluted)
BGC
BGC
BMRN
BMRN
Q1 26
$0.17
$0.54
Q4 25
$0.03
$-0.22
Q3 25
$0.06
$-0.16
Q2 25
$0.11
$1.23
Q1 25
$0.11
$0.95
Q4 24
$0.04
$0.65
Q3 24
$0.03
$0.55
Q2 24
$0.08
$0.55

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BGC
BGC
BMRN
BMRN
Cash + ST InvestmentsLiquidity on hand
$781.0M
$2.2B
Total DebtLower is stronger
Stockholders' EquityBook value
$1.1B
$6.2B
Total Assets
$5.9B
$8.6B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BGC
BGC
BMRN
BMRN
Q1 26
$781.0M
$2.2B
Q4 25
$851.5M
$1.3B
Q3 25
$774.9M
$1.3B
Q2 25
$827.8M
$1.2B
Q1 25
$966.4M
$1.0B
Q4 24
$711.6M
$942.8M
Q3 24
$563.5M
$675.4M
Q2 24
$571.7M
$972.1M
Total Debt
BGC
BGC
BMRN
BMRN
Q1 26
Q4 25
$1.5B
Q3 25
$1.8B
Q2 25
$1.8B
Q1 25
$1.1B
Q4 24
$1.1B
Q3 24
$1.4B
Q2 24
$1.4B
Stockholders' Equity
BGC
BGC
BMRN
BMRN
Q1 26
$1.1B
$6.2B
Q4 25
$972.5M
$6.1B
Q3 25
$965.3M
$6.1B
Q2 25
$930.5M
$6.0B
Q1 25
$963.8M
$5.8B
Q4 24
$898.5M
$5.7B
Q3 24
$860.1M
$5.4B
Q2 24
$858.1M
$5.3B
Total Assets
BGC
BGC
BMRN
BMRN
Q1 26
$5.9B
$8.6B
Q4 25
$4.4B
$7.6B
Q3 25
$5.8B
$7.6B
Q2 25
$4.9B
$7.5B
Q1 25
$4.9B
$7.1B
Q4 24
$3.6B
$7.0B
Q3 24
$4.4B
$6.9B
Q2 24
$4.3B
$7.1B
Debt / Equity
BGC
BGC
BMRN
BMRN
Q1 26
Q4 25
1.58×
Q3 25
1.90×
Q2 25
1.97×
Q1 25
1.19×
Q4 24
1.27×
Q3 24
1.68×
Q2 24
1.68×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BGC
BGC
BMRN
BMRN
Operating Cash FlowLast quarter
$220.7M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
2.08×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BGC
BGC
BMRN
BMRN
Q1 26
$220.7M
Q4 25
$180.4M
$99.6M
Q3 25
$141.9M
$368.7M
Q2 25
$71.2M
$185.3M
Q1 25
$839.0K
$174.4M
Q4 24
$251.9M
$185.6M
Q3 24
$88.3M
$221.5M
Q2 24
$-53.0M
$118.8M
Free Cash Flow
BGC
BGC
BMRN
BMRN
Q1 26
Q4 25
$175.1M
$58.9M
Q3 25
$137.2M
$340.2M
Q2 25
$65.0M
$168.2M
Q1 25
$-4.4M
$157.6M
Q4 24
$245.6M
$166.1M
Q3 24
$78.8M
$203.0M
Q2 24
$-63.5M
$97.4M
FCF Margin
BGC
BGC
BMRN
BMRN
Q1 26
Q4 25
27.4%
6.7%
Q3 25
22.1%
43.8%
Q2 25
10.0%
20.4%
Q1 25
-0.8%
21.2%
Q4 24
51.7%
22.2%
Q3 24
17.5%
27.2%
Q2 24
-14.6%
13.7%
Capex Intensity
BGC
BGC
BMRN
BMRN
Q1 26
Q4 25
0.8%
4.7%
Q3 25
0.8%
3.7%
Q2 25
1.0%
2.1%
Q1 25
1.0%
2.3%
Q4 24
1.3%
2.6%
Q3 24
2.1%
2.5%
Q2 24
2.4%
3.0%
Cash Conversion
BGC
BGC
BMRN
BMRN
Q1 26
2.08×
Q4 25
12.55×
Q3 25
5.09×
Q2 25
1.24×
0.77×
Q1 25
0.02×
0.94×
Q4 24
9.99×
1.49×
Q3 24
5.99×
2.09×
Q2 24
-1.40×
1.11×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BGC
BGC

Commissions$752.9M79%
Principal transactions$142.9M15%
Data, network and post-trade$34.5M4%
Other revenues$10.3M1%
Fees from related parties$4.3M0%

BMRN
BMRN

Segment breakdown not available.

Related Comparisons